相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Effects of arsenic trioxide on the cellular proliferation, apoptosis and differentiation of human neuroblastoma cells
William M. W. Cheung et al.
CANCER LETTERS (2007)
Arsenic compounds in the treatment of multiple myeloma: A new role for a historical remedy
James R. Berenson et al.
CLINICAL LYMPHOMA & MYELOMA (2006)
被撤回的出版物: Berberine inhibits growth, induces G1 arrest and apoptosis in human epidermoid carcinoma A431 cells by regulating Cdki-Cdk-cyclin cascade, disruption of mitochondrial membrane potential and cleavage of caspase 3 and PARP (Retracted article. See vol. 39, pg. 739, 2018)
Sudheer K. Mantena et al.
CARCINOGENESIS (2006)
Berberine -: antiproliferative activity in vitro and induction of apoptosis/necrosis of the U937 and B16 cells
Silvia Letasiova et al.
CANCER LETTERS (2006)
Preclinical and clinical development of novel agents that target the protein kinase C family
Maria Serova et al.
SEMINARS IN ONCOLOGY (2006)
Inhibitory effect of berberine on the invasion of human lung cancer cells via decreased productions of urokinase-plasminogen activator and matrix metalloproteinase-2
Pei-Ling Peng et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2006)
Elemental arsenic entered the cerebrospinal fluid during oral arsenic trioxide treatment of meningeal relapse of acute promyelocytic leukemia
WY Au et al.
BLOOD (2006)
Inhibitory effect of caffeic acid phenethyl ester on the growth of C6 glioma cells in vitro and in vivo
HC Kuo et al.
CANCER LETTERS (2006)
Protein kinase C and the regulation of the actin cytoskeleton
C Larsson
CELLULAR SIGNALLING (2006)
Berberine induces apoptosis through a mitochondria/caspases pathway in human hepatoma cells
JM Hwang et al.
ARCHIVES OF TOXICOLOGY (2006)
Enhancement of esculetin on Taxol-induced apoptosis in human hepatoma HepG2 cells
HC Kuo et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2006)
Membrane type-matrix metalloproteinases and tumor progression
NE Sounni et al.
BIOCHIMIE (2005)
Arsenic trioxide prevents radiation-enhanced tumor invasiveness and inhibits matrix metalloproteinase-9 through downregulation of nuclear factor κB
LH Wei et al.
ONCOGENE (2005)
Protein kinase C isozymes as potential targets for anticancer therapy
J Hofmann
CURRENT CANCER DRUG TARGETS (2004)
The anti-inflammatory potential of berberine in vitro and in vivo
CL Kuo et al.
CANCER LETTERS (2004)
Protein kinase C α/β inhibitor Go6976 promotes formation of cell junctions and inhibits invasion of urinary bladder carcinoma cells
J Koivunen et al.
CANCER RESEARCH (2004)
Protein kinase C: a target for anticancer drugs?
HJ Mackay et al.
ENDOCRINE-RELATED CANCER (2003)
Proteases in brain tumour progression
N Levicar et al.
ACTA NEUROCHIRURGICA (2003)
Molecular mechanisms of glioma invasiveness: The role of proteases
JS Rao
NATURE REVIEWS CANCER (2003)
Acute and chronic arsenic toxicity
RN Ratnaike
POSTGRADUATE MEDICAL JOURNAL (2003)
Antisense therapy directed to protein kinase C-alpha (Affinitak, LY900003/ISIS 3521): Potential role in breast cancer
D Roychowdhury et al.
SEMINARS IN ONCOLOGY (2003)
Inhibitory effect of berberine on tert-butyl hydroperoxide-induced oxidative damage in rat liver
JM Hwang et al.
ARCHIVES OF TOXICOLOGY (2002)
The molecular mechanisms of arsenic-induced cell transformation and apoptosis
ZG Dong
ENVIRONMENTAL HEALTH PERSPECTIVES (2002)
Arsenic trioxide: Acute promyelocytic leukemia and beyond
T Bachleitner-Hofmann et al.
LEUKEMIA & LYMPHOMA (2002)
Arsenic Trioxide Arrests Cells Early in Mitosis Leading to Apoptosis
H. Dorota Halicka et al.
CELL CYCLE (2002)
The paradox of arsenic: molecular mechanisms of cell transformation and chemotherapeutic effects
AM Bode et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2002)
Expanding the use of arsenic trioxide: Leukemias and beyond
Z Chen et al.
SEMINARS IN HEMATOLOGY (2002)
Anti-cancer drugs of today and tomorrow: Are we close to making the turn from treating to curing cancer?
S Pervaiz
CURRENT PHARMACEUTICAL DESIGN (2002)
Targeting protein kinase C: New therapeutic opportunities against high-grade malignant gliomas?
AB da Rocha et al.
ONCOLOGIST (2002)
Arsenic trioxide, a therapeutic agent for APL
TD Zhang et al.
ONCOGENE (2001)
Arsenic compounds as anticancer agents
ZY Wang
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2001)
High PKC α and low E-cadherin expression contribute to high migratory activity of colon carcinoma cells
K Masur et al.
MOLECULAR BIOLOGY OF THE CELL (2001)
Inhibition of chemical carcinogenesis by berberine in rats and mice
KV Anis et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2001)
Clinical trials of arsenic trioxide in hematologic and slid tumors: Overview of the national cancer institute cooperative research and development studies
AJ Murgo
ONCOLOGIST (2001)
Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARα and PLZF-RARα oncoproteins
EM Rego et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Arsenic-induced apoptosis in malignant cells in vitro
Y Akao et al.
LEUKEMIA & LYMPHOMA (2000)
Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia
X Cai et al.
LEUKEMIA (2000)
Apoptosis induction by arsenic: mechanisms of action and possible clinical applications for treating therapy-resistant cancers
A Bode et al.
DRUG RESISTANCE UPDATES (2000)
Protein kinase C activation by phorbol eater increases in vitro invasion through regulation of matrix metalloproteinases/tissue inhibitors of metalloproteinases system in D54 human glioblastoma cells
MJ Park et al.
NEUROSCIENCE LETTERS (2000)
分享论文
